Claritev Corporation Reports Fourth Quarter 2025 Results
Claritev Corporation reports financial results for the fourth quarter ended December 31, 2025 highlighting growth.
Q4 2025Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%)
Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024)
Full-year 2026 Guidance initiated:
- Revenue range of $980 million to $1 billion
- Free cash flow of $0 million to $10 million
- Capital expenditures of $160 million to $170 million
Company Board of Directors approves $75 million, five-year share repurchase program
MCLEAN, VA — February 23, 2026 — Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter ended December 31, 2025.
